Skip to main content Back to Top

A New Landscape: Biosimilars in Autoimmune Indications

August 25, 2023


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher Podcasts Listen on Spotify Subscribe to TuneIn PodcastsSubscribe to iHeartRadio

Learn from experts in the field about biosimilars in rheumatology and gastroenterology, biosimilar-related terms such as interchangeability and nocebo effect, and considerations unique to adalimumab biosimilars.


Shubha BhatShubha Bhat, PharmD, MS, FCCP, BCACP is a clinical pharmacy specialist in the Digestive Disease & Surgery Institute at the Cleveland Clinic. She received her PharmD from Northeastern University and completed post-graduate residency and fellowship training at Boston Medical Center, University of Illinois at Chicago, and University of Colorado. In her current practice, Dr. Bhat provides medication education, monitors medication outcomes, manages adverse effects, and coordinates health maintenance needs for patients with gastrointestinal conditions. She is also involved in precepting trainees and conducts research focused on ambulatory care pharmacists' impact on patient outcomes and inflammatory bowel disease.

Jorge GarciaJorge Garcia, PharmD, MS, MHA, MBA, FACHE obtained his Doctor of Pharmacy and Master of Business Administration from Nova Southeastern University (NSU) in 2010. He then transitioned to the University of Pittsburgh Medical Center (UPMC) to pursue an American Society of Health-System Pharmacy (ASHP)-accredited PGY-1 & PGY-2 Health-System Pharmacy Administration Residency and a Master of Science in Pharmacy Administration. He also completed an Master of Healthcare Administration from Florida Atlantic University (FAU). Dr. García has previously served in the roles of inpatient pharmacy operations coordinator as well as director of pharmacy for system-wide oncology pharmacy services.


Relevant Financial Relationship Disclosures

The following persons in control of this activity’s content have relevant financial relationships:

Shubha Bhat – Pfizer (advisory board); Boehringer Ingelheim (advisory board); Abbvie (consultant); Pharmacosmos (advisory board); Bristol Meyers Squibb (advisory board)

No one else in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.


Biosimilar Adoption: Past Experiences and Future Opportunities

Biosimilar Adoption Breaking through Barriers Resource Center

More in This Series

A New Landscape: Biosimilars in Multiple Sclerosis


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast is provided by ASHP and sponsored in part by Amgen. Supported in part by an independent medical education grant from Sandoz Inc., a Novartis Division.